MDBH MDB CAPITAL HOLDINGS LLC

Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol

Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol

Trading Under New Ticker of “EXOZ” Expected to Begin February 12, 2025

Monrovia, CA, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc., (NASDAQ: IZTC) ("Invizyne"), a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, announced a corporate name change to eXoZymes, Inc. (“eXoZymes”) and an application for a new ticker symbol. The company expects trading under the new ticker symbol of “EXOZ” to begin on February 12, 2025, subject to final approvals.

In connection with the corporate name change, Company branding, including the corporate website, will be updated accordingly.

No action is required by existing shareholders with respect to the name and ticker symbol change. The Committee on Uniform Securities Identification Procedures (CUSIP) also confirmed the CUSIP number assigned to the Company's common stock will remain unchanged.

About Invizyne

Invizyne Technologies, Inc. is a cell-free enzyme-based biomanufacturing technology company headquartered in Monrovia, California. Invizyne is redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals, such as Active Pharmaceutical Ingredients (APIs), biofuels, food flavors, fragrances, cosmetics, etc. Management of Invizyne believes that its biomanufacturing platform, will be a significant alternative to the current methods of chemical compound production, which are generally chemical synthesis, natural extraction, and synthetic biology.

For more information, please visit  

Forward-Looking Statements

This press release contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “aim”, "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements.

Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Invizyne's control. Invizyne's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors. The forward-looking statements included in this press release represent Invizyne's views as of the date of this press release. Invizyne anticipates that subsequent events and developments will cause its views to change. Invizyne undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Invizyne's views as of any date subsequent to the date of this press release.

Media contacts:

Lasse Görlitz, VP of Communications

(858) 319-7135

 

Investor Relations Contact: 

 





EN
10/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MDB CAPITAL HOLDINGS LLC

 PRESS RELEASE

New PatentVest Pulse Report Maps the Competitive and IP Landscape of t...

New PatentVest Pulse Report Maps the Competitive and IP Landscape of the $133B Cardiac Diagnostics Market Designed for investors, board members, and CEOs, the latest PatentVest Pulse report offers a strategic view of who’s leading and why in the rapidly evolving cardiac diagnostics market Dallas, TX, Oct. 28, 2025 (GLOBE NEWSWIRE) -- PatentVest, the first fully integrated IP intelligence and strategy firm, has released its latest PatentVest Pulse report, “.”The report shows how the convergence of consumer technology, ambulatory monitoring, and traditional medical systems is redefining t...

 PRESS RELEASE

PatentVest Welcomes Dr. Sarah Cork as Senior Patent Attorney, Expandin...

PatentVest Welcomes Dr. Sarah Cork as Senior Patent Attorney, Expanding Life Sciences IP Leadership Sarah Cork Ph.D. - Patent Attorney Dallas, TX, Sept. 24, 2025 (GLOBE NEWSWIRE) -- PatentVest, a division of MDB Capital Holdings (Nasdaq: MDBH), is pleased to announce that Dr. Sarah Cork is collaborating with the firm as a Senior Patent Attorney. Her arrival underscores PatentVest’s continued growth in the life sciences sector and strengthens its ability to deliver sophisticated intellectual property strategies that drive competitive advantage for clients. Dr. Cork brings more than a d...

 PRESS RELEASE

MDB Capital Holdings Provides Second Quarter 2025 Update

MDB Capital Holdings Provides Second Quarter 2025 Update Management to Host Conference Call Today at 4:30 p.m. ET Addison, TX, Aug. 27, 2025 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading “Big Idea” companies, today provides an operational update for the quarter ended June 30, 2025, and subsequent developments. Second Quarter 2025 and Subsequent Operational Highlights Launched private offering for Paulex Bio, a company developing a transformational oral medication designed to eliminate th...

 PRESS RELEASE

PatentVest and Docana Announce Strategic Partnership to Accelerate IP ...

PatentVest and Docana Announce Strategic Partnership to Accelerate IP Strategy and AI Innovation Addison, TX, Aug. 27, 2025 (GLOBE NEWSWIRE) -- PatentVest, Inc., a leader in intellectual property strategy and prosecution, announces a strategic partnership with Docana, Inc., an emerging innovator in AI-powered enterprise knowledge extraction. This collaboration represents a shared commitment to advancing scalable innovation through the integration of robust IP frameworks and cutting-edge artificial intelligence. As part of the partnership, PatentVest will provide strategic legal and IP co...

 PRESS RELEASE

PatentVest Releases First-Ever Quantum Computing Rankings

PatentVest Releases First-Ever Quantum Computing Rankings Designed for investors, board members, and CEOs, the latest PatentVest Pulse Report reveals which companies are emerging as true leaders as quantum computing shifts from R&D to commercialization Addison, TX, Aug. 19, 2025 (GLOBE NEWSWIRE) -- PatentVest, the first fully integrated IP intelligence and legal strategy firm, today announced the release of its , the first-ever rankings of leadership in the emerging $850B quantum computing market. Designed for investors, board members, and CEOs, the report profiles 38 companies worldwid...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch